Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease

Carmine Zoccali, Francesca Mallamaci, Giovanni Tripepi, Francesco A. Benedetto, Saverio Parlongo, Sebastiano Cutrupi, Graziella Bonanno, Francesco Rapisarda, Pasquale Fatuzzo, Giuseppe Seminara, Alessandro Cataliotti, Lorenzo S. Malatino

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: Neuropeptide Y (NPY) is released during sympathetic stimulation and mediates the central effects of the adipostatic hormone leptin. The plasma concentration of NPY and leptin is increased in patients with end stage renal disease (ESRD), but it is unknown whether these substances are related to biochemical markers of sympathetic activity and to alterations in left ventricular (LV) mass and function in these patients. Design: We investigated the relationship between NPY, norepinephrine (NE), leptin and echocardiographic measurements in a cross-sectional study in 198 patients with ESRD. Results: NPY was directly related to plasma NE and heart rate but it was largely independent of arterial pressure and of retention of metabolic waste products. NPY was significantly higher in patients with LV hypertrophy and in those with LV systolic dysfunction than in those without these alterations. Of note, NPY emerged as an independent correlate of LV mass index and of LV ejection fraction (LVEF) (both P ≤ 0.002) in multiple linear regression analyses including a series of cardiovascular risk factors. Furthermore in a multiple logistic regression model patients in the top NPY tertile had a risk for LV concentric hypertrophy that was 18.10 (95% confidence interval: 5.87-55.83) times higher than in those in the first tertile (P < 0.001). Leptin was unrelated to NPY as well as to LV mass and to systolic function. Conclusions: Elevated NPY is independently associated with LV concentric hypertrophy and systolic dysfunction in ESRD. It remains to be seen whether these links contribute to the high cardiovascular mortality in these patients.

Original languageEnglish (US)
Pages (from-to)1355-1362
Number of pages8
JournalJournal of Hypertension
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2003
Externally publishedYes

Fingerprint

Neuropeptide Y
Left Ventricular Function
Chronic Kidney Failure
Leptin
Left Ventricular Hypertrophy
Norepinephrine
Logistic Models
Waste Products
Left Ventricular Dysfunction
Stroke Volume
Linear Models
Arterial Pressure
Cross-Sectional Studies
Biomarkers
Heart Rate
Regression Analysis
Hormones
Confidence Intervals
Mortality

Keywords

  • Cardiovascular risk
  • Dialysis
  • Left ventricular hypertrophy
  • Leptin
  • Neuropeptide Y
  • Norepinephrine
  • Systolic dysfunction

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Zoccali, C., Mallamaci, F., Tripepi, G., Benedetto, F. A., Parlongo, S., Cutrupi, S., ... Malatino, L. S. (2003). Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. Journal of Hypertension, 21(7), 1355-1362. https://doi.org/10.1097/00004872-200307000-00025

Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. / Zoccali, Carmine; Mallamaci, Francesca; Tripepi, Giovanni; Benedetto, Francesco A.; Parlongo, Saverio; Cutrupi, Sebastiano; Bonanno, Graziella; Rapisarda, Francesco; Fatuzzo, Pasquale; Seminara, Giuseppe; Cataliotti, Alessandro; Malatino, Lorenzo S.

In: Journal of Hypertension, Vol. 21, No. 7, 01.07.2003, p. 1355-1362.

Research output: Contribution to journalArticle

Zoccali, C, Mallamaci, F, Tripepi, G, Benedetto, FA, Parlongo, S, Cutrupi, S, Bonanno, G, Rapisarda, F, Fatuzzo, P, Seminara, G, Cataliotti, A & Malatino, LS 2003, 'Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease', Journal of Hypertension, vol. 21, no. 7, pp. 1355-1362. https://doi.org/10.1097/00004872-200307000-00025
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S et al. Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. Journal of Hypertension. 2003 Jul 1;21(7):1355-1362. https://doi.org/10.1097/00004872-200307000-00025
Zoccali, Carmine ; Mallamaci, Francesca ; Tripepi, Giovanni ; Benedetto, Francesco A. ; Parlongo, Saverio ; Cutrupi, Sebastiano ; Bonanno, Graziella ; Rapisarda, Francesco ; Fatuzzo, Pasquale ; Seminara, Giuseppe ; Cataliotti, Alessandro ; Malatino, Lorenzo S. / Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. In: Journal of Hypertension. 2003 ; Vol. 21, No. 7. pp. 1355-1362.
@article{06fc347dc87841aeae363a2b5168ed01,
title = "Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease",
abstract = "Objective: Neuropeptide Y (NPY) is released during sympathetic stimulation and mediates the central effects of the adipostatic hormone leptin. The plasma concentration of NPY and leptin is increased in patients with end stage renal disease (ESRD), but it is unknown whether these substances are related to biochemical markers of sympathetic activity and to alterations in left ventricular (LV) mass and function in these patients. Design: We investigated the relationship between NPY, norepinephrine (NE), leptin and echocardiographic measurements in a cross-sectional study in 198 patients with ESRD. Results: NPY was directly related to plasma NE and heart rate but it was largely independent of arterial pressure and of retention of metabolic waste products. NPY was significantly higher in patients with LV hypertrophy and in those with LV systolic dysfunction than in those without these alterations. Of note, NPY emerged as an independent correlate of LV mass index and of LV ejection fraction (LVEF) (both P ≤ 0.002) in multiple linear regression analyses including a series of cardiovascular risk factors. Furthermore in a multiple logistic regression model patients in the top NPY tertile had a risk for LV concentric hypertrophy that was 18.10 (95{\%} confidence interval: 5.87-55.83) times higher than in those in the first tertile (P < 0.001). Leptin was unrelated to NPY as well as to LV mass and to systolic function. Conclusions: Elevated NPY is independently associated with LV concentric hypertrophy and systolic dysfunction in ESRD. It remains to be seen whether these links contribute to the high cardiovascular mortality in these patients.",
keywords = "Cardiovascular risk, Dialysis, Left ventricular hypertrophy, Leptin, Neuropeptide Y, Norepinephrine, Systolic dysfunction",
author = "Carmine Zoccali and Francesca Mallamaci and Giovanni Tripepi and Benedetto, {Francesco A.} and Saverio Parlongo and Sebastiano Cutrupi and Graziella Bonanno and Francesco Rapisarda and Pasquale Fatuzzo and Giuseppe Seminara and Alessandro Cataliotti and Malatino, {Lorenzo S.}",
year = "2003",
month = "7",
day = "1",
doi = "10.1097/00004872-200307000-00025",
language = "English (US)",
volume = "21",
pages = "1355--1362",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease

AU - Zoccali, Carmine

AU - Mallamaci, Francesca

AU - Tripepi, Giovanni

AU - Benedetto, Francesco A.

AU - Parlongo, Saverio

AU - Cutrupi, Sebastiano

AU - Bonanno, Graziella

AU - Rapisarda, Francesco

AU - Fatuzzo, Pasquale

AU - Seminara, Giuseppe

AU - Cataliotti, Alessandro

AU - Malatino, Lorenzo S.

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Objective: Neuropeptide Y (NPY) is released during sympathetic stimulation and mediates the central effects of the adipostatic hormone leptin. The plasma concentration of NPY and leptin is increased in patients with end stage renal disease (ESRD), but it is unknown whether these substances are related to biochemical markers of sympathetic activity and to alterations in left ventricular (LV) mass and function in these patients. Design: We investigated the relationship between NPY, norepinephrine (NE), leptin and echocardiographic measurements in a cross-sectional study in 198 patients with ESRD. Results: NPY was directly related to plasma NE and heart rate but it was largely independent of arterial pressure and of retention of metabolic waste products. NPY was significantly higher in patients with LV hypertrophy and in those with LV systolic dysfunction than in those without these alterations. Of note, NPY emerged as an independent correlate of LV mass index and of LV ejection fraction (LVEF) (both P ≤ 0.002) in multiple linear regression analyses including a series of cardiovascular risk factors. Furthermore in a multiple logistic regression model patients in the top NPY tertile had a risk for LV concentric hypertrophy that was 18.10 (95% confidence interval: 5.87-55.83) times higher than in those in the first tertile (P < 0.001). Leptin was unrelated to NPY as well as to LV mass and to systolic function. Conclusions: Elevated NPY is independently associated with LV concentric hypertrophy and systolic dysfunction in ESRD. It remains to be seen whether these links contribute to the high cardiovascular mortality in these patients.

AB - Objective: Neuropeptide Y (NPY) is released during sympathetic stimulation and mediates the central effects of the adipostatic hormone leptin. The plasma concentration of NPY and leptin is increased in patients with end stage renal disease (ESRD), but it is unknown whether these substances are related to biochemical markers of sympathetic activity and to alterations in left ventricular (LV) mass and function in these patients. Design: We investigated the relationship between NPY, norepinephrine (NE), leptin and echocardiographic measurements in a cross-sectional study in 198 patients with ESRD. Results: NPY was directly related to plasma NE and heart rate but it was largely independent of arterial pressure and of retention of metabolic waste products. NPY was significantly higher in patients with LV hypertrophy and in those with LV systolic dysfunction than in those without these alterations. Of note, NPY emerged as an independent correlate of LV mass index and of LV ejection fraction (LVEF) (both P ≤ 0.002) in multiple linear regression analyses including a series of cardiovascular risk factors. Furthermore in a multiple logistic regression model patients in the top NPY tertile had a risk for LV concentric hypertrophy that was 18.10 (95% confidence interval: 5.87-55.83) times higher than in those in the first tertile (P < 0.001). Leptin was unrelated to NPY as well as to LV mass and to systolic function. Conclusions: Elevated NPY is independently associated with LV concentric hypertrophy and systolic dysfunction in ESRD. It remains to be seen whether these links contribute to the high cardiovascular mortality in these patients.

KW - Cardiovascular risk

KW - Dialysis

KW - Left ventricular hypertrophy

KW - Leptin

KW - Neuropeptide Y

KW - Norepinephrine

KW - Systolic dysfunction

UR - http://www.scopus.com/inward/record.url?scp=0042093789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042093789&partnerID=8YFLogxK

U2 - 10.1097/00004872-200307000-00025

DO - 10.1097/00004872-200307000-00025

M3 - Article

C2 - 12817184

AN - SCOPUS:0042093789

VL - 21

SP - 1355

EP - 1362

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 7

ER -